Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cue Biopharma Inc (NQ: CUE )

2.110 +0.230 (+12.23%)
Streaming Delayed Price Updated: 2:40 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cue Biopharma Inc

< Previous 1 2 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
Via Benzinga
CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023
CUE stock results show that Cue Biopharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023. 
Via InvestorPlace
Where Cue Biopharma Stands With Analysts
Via Benzinga
Cue Biopharma Earnings Perspective: Return On Capital Employed
Via Benzinga
Cue Biopharma's Earnings Outlook
Via Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
The Truth About IPO Investing
When most companies go public, they are somewhat mature. Tech company initial public offerings, or IPOs, are a bit different, however. These companies are often not yet profitable. And biotech IPOs are... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Biotech Stocks to Buy as Companies Ink Major Deals
Pharmaceutical and biotech companies will soon face generic competition, creating big opportunity for these top biotech stocks to buy. 
Via InvestorPlace
3 Biotech Stocks Sitting on Huge-Upside Catalysts
The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks. 
Via InvestorPlace
7 Hot Growth Stocks Poised to Triple in 2023
These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher. 
Via InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
Earnings Scheduled For March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, traders! We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) rose 70.8% to $0.41 in pre-market trading. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off
Cue Biopharma (NASDAQ: CUE) has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms' Tumor 1 (WT1)-positive recurrent/metastatic... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 87 companies hit new 52-week lows. 
Via Benzinga
Cue Biopharma's Return On Capital Employed Overview
Benzinga Pro data, Cue Biopharma (NASDAQ:CUE) reported Q1 sales of $1.00 million. Earnings fell to a loss of $14.26 million, resulting in a 70.02% decrease from last quarter. 
Via Benzinga
FDA Accepts IND for Cue Biopharma's CUE-102 in the treatment of Wilms' Tumor 1 (WT1)
Cue Biopharma, Inc. (NASDAQ: CUE) received the U.S. Food and Drug Administration (FDA) acceptance of the Investigational New Drug (IND) application for the evaluation of CUE-102 in the treatment of... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares moved upwards by 163.3% to $5.95 during Tuesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Looking Into Cue Biopharma's Return On Capital Employed
According to data from Benzinga Pro, during Q4, Cue Biopharma's (NASDAQ:CUE) reported sales totaled $8.25 million. Despite a 35.47% increase in earnings, the company posted a loss... 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership with The Walt Disney Co. Cuentas Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.